REBECCA SPENCER: Open Payments
NPI 1861247728 · WINCHESTER, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,266 in 74 payments from 17 companies in 2025. Trend: 2023 $0 · 2024 $582 · 2025 $1,266
Food & beverage: $1,266
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 14 | $230 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $160 |
| Ardelyx, Inc. | 8 | $154 |
| ABBVIE INC. | 12 | $144 |
| Ipsen Biopharmaceuticals, Inc | 5 | $127 |
| GENZYME CORPORATION | 4 | $105 |
| Gilead Sciences, Inc. | 4 | $80 |
| Regeneron Healthcare Solutions, Inc. | 2 | $49 |
| Intercept Pharmaceuticals, Inc. | 3 | $49 |
| Madrigal Pharmaceuticals | 1 | $27 |
Products named: XIFAXAN, ENTYVIO, IBSRELA, DUPIXENT, IQIRVO, RINVOQ, OCALIVA, REZDIFFRA.
Industry payments across VA — which companies pay providers there.
